Thrombocytosis.

Abstract excerpt

Major progress in understanding the pathogenesis in patients with thrombocytosis has been made by identifying mutations in the key regulators of thrombopoietin: the thrombopoietin receptor MPL and JAK2. Together, these mutations can be found in 50% to 60% of patients with essential thrombocythemia or primary myelofibrosis and in 10% to 20% of hereditary thrombocytosis. A decrease in expression of the Mpl protein...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Polycythemia Vera
• Share to Primary Myelofibrosis
• Share to Receptors, Thrombopoietin